Literature DB >> 11726085

Movement dysfunction and hepatic encephalopathy.

G P Layrargues1.   

Abstract

Hepatic encephalopathy is characterized by a variety of neurological symptoms. The occurrence of movement disorders is exceptional and is usually part of a clinical syndrome called acquired hepatocerebral degeneration, which is a subtype of chronic recurrent hepatic encephalopathy. The clinical picture is usually progressive and pathologic findings include regional astroglial and neuronal abnormalities found predominantly in cortex and basal ganglia. As for hepatic encephalopathy in general, the pathophysiology of this disorder is unknown but hyperammonemia and/or brain manganese overload may play a role. Medical treatment is often disappointing but in selected cases liver transplantation may be curative.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11726085     DOI: 10.1023/a:1011658311004

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  31 in total

1.  Magnetic resonance imaging and proton spectroscopic alterations correlate with parkinsonian signs in patients with cirrhosis.

Authors:  L Spahr; F Vingerhoets; F Lazeyras; J Delavelle; R DuPasquier; E Giostra; G Mentha; F Terrier; A Hadengue
Journal:  Gastroenterology       Date:  2000-09       Impact factor: 22.682

Review 2.  Proton magnetic resonance spectroscopy in portal-systemic encephalopathy.

Authors:  H Köstler
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

3.  Direction of splenic venous flow assessed by pulsed Doppler flowmetry in patients with a large splenorenal shunt. Relation to spontaneous hepatic encephalopathy.

Authors:  K Ohnishi; M Saito; S Sato; T Nakayama; M Takashi; S Iida; F Nomura; H Koen; K Okuda
Journal:  Gastroenterology       Date:  1985-07       Impact factor: 22.682

4.  Increased manganese concentrations in pallidum of cirrhotic patients.

Authors:  G Pomier-Layrargues; L Spahr; R F Butterworth
Journal:  Lancet       Date:  1995-03-18       Impact factor: 79.321

5.  Fine structure of inclusion body in the nucleus of Alzheimer glia type II in the brain of hepatocerebral degeneration.

Authors:  T Miyakawa; R Kuramoto; A Shimoji; Y Higuchi
Journal:  Acta Neuropathol       Date:  1982       Impact factor: 17.088

6.  Distribution of cerebral lesions in acquired hepatocerebral degeneration.

Authors:  M H Finlayson; B Superville
Journal:  Brain       Date:  1981-03       Impact factor: 13.501

7.  Treatment of chronic portal systemic encephalopathy with bromocriptine: a double-blind controlled trial.

Authors:  M Uribe; A Farca; M A Márquez; G Garcĭa-Ramos; L Guevara
Journal:  Gastroenterology       Date:  1979-06       Impact factor: 22.682

Review 8.  Ammonia: key factor in the pathogenesis of hepatic encephalopathy.

Authors:  R F Butterworth; J F Giguère; J Michaud; J Lavoie; G P Layrargues
Journal:  Neurochem Pathol       Date:  1987 Feb-Apr

9.  Treatment of cirrhotic hepatic encephalopathy with L-dopa. A controlled trial.

Authors:  H Michel; M Solere; P Granier; G Cauvet; J P Bali; F Pons; H Bellet-Hermann
Journal:  Gastroenterology       Date:  1980-08       Impact factor: 22.682

10.  Manganese and chronic hepatic encephalopathy.

Authors:  D Krieger; S Krieger; O Jansen; P Gass; L Theilmann; H Lichtnecker
Journal:  Lancet       Date:  1995-07-29       Impact factor: 79.321

View more
  7 in total

Review 1.  Acquired hepatocerebral degeneration.

Authors:  Joseph Ferrara; Joseph Jankovic
Journal:  J Neurol       Date:  2009-02-17       Impact factor: 4.849

Review 2.  Acquired hepatocerebral degeneration: a case report.

Authors:  Wei-Xing Chen; Ping Wang; Sen-Xiang Yan; You-Ming Li; Chao-Hui Yu; Ling-Ling Jiang
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

Review 3.  Altered modulation of motor activity by group I metabotropic glutamate receptors in the nucleus accumbens in hyperammonemic rats.

Authors:  Omar Cauli; Marta Llansola; Regina Rodrigo; Nisrin El Mlili; Mohammed Errami; Vicente Felipo
Journal:  Metab Brain Dis       Date:  2005-12       Impact factor: 3.584

4.  Acquired hepatocerebral degeneration: A case report.

Authors:  Clarice Listik; Gislaine Cristina Lopes Machado-Porto; Maira Okada de Oliveira; Fábio Henrique de Gobbi Porto
Journal:  Dement Neuropsychol       Date:  2012 Jan-Mar

5.  Induction of NOS and nitrotyrosine expression in the rat striatum following experimental hepatic encephalopathy.

Authors:  Isabel Suárez; Guillermo Bodega; Miguel Rubio; Benjamín Fernández
Journal:  Metab Brain Dis       Date:  2009-09       Impact factor: 3.584

6.  Cognitive functioning in chronic acquired hepatocerebral degeneration.

Authors:  Andrea Stracciari; Katia Mattarozzi; Roberto D'Alessandro; Elisa Baldin; Maria Guarino
Journal:  Metab Brain Dis       Date:  2008-04-24       Impact factor: 3.584

Review 7.  Parkinsonism in cirrhosis: pathogenesis and current therapeutic options.

Authors:  Roger F Butterworth
Journal:  Metab Brain Dis       Date:  2012-10-20       Impact factor: 3.584

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.